Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Barry

Showing results (571-580 of 674) with videos related to

Pageof 68
Sort By:
The Oncologist|May 12, 2021
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer PatientsSara M Tolaney, David R Ziehr, Hao Guo, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 12, 2013
Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapyLee W Jones, Diane R Fels, Miranda West, et al.
International Journal of Cancer|November 13, 2019
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancerAndrea P Myers, Panagiotis A Konstantinopoulos, William T Barry, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2015
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patientsSara M Tolaney, Yves Boucher, Dan G Duda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2014
Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901Vanessa B Sheppard, Leigh Anne Faul, George Luta, et al.
Cancer Research|January 9, 2020
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid FeaturesMiriam Marqués, Robin Tranchant, Blanca Risa-Ebrí, et al.
NPJ Breast Cancer|September 27, 2017
Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study designJennifer A Ligibel, William T Barry, Catherine Alfano, et al.
Nature Immunology|November 24, 2020
MEK inhibition reprograms CD8<sup>+</sup> T lymphocytes into memory stem cells with potent antitumor effectsVivek Verma, Nazli Jafarzadeh, Shannon Boi, et al.
Cancer Research|October 21, 2016
mTORC2 Signaling Drives the Development and Progression of Pancreatic CancerDavid R Driscoll, Saadia A Karim, Makoto Sano, et al.
Cancer Research|July 18, 2024
Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast CancerAlissandra L Hillis, Timothy D Martin, Haley E Manchester, et al.
Pageof 68

Showing results (571-580 of 674) with videos related to

Sort By:
Pageof 68
The Oncologist|May 12, 2021
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer PatientsSara M Tolaney, David R Ziehr, Hao Guo, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 12, 2013
Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapyLee W Jones, Diane R Fels, Miranda West, et al.
International Journal of Cancer|November 13, 2019
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancerAndrea P Myers, Panagiotis A Konstantinopoulos, William T Barry, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 19, 2015
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patientsSara M Tolaney, Yves Boucher, Dan G Duda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2014
Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901Vanessa B Sheppard, Leigh Anne Faul, George Luta, et al.
Cancer Research|January 9, 2020
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid FeaturesMiriam Marqués, Robin Tranchant, Blanca Risa-Ebrí, et al.
NPJ Breast Cancer|September 27, 2017
Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study designJennifer A Ligibel, William T Barry, Catherine Alfano, et al.
Nature Immunology|November 24, 2020
MEK inhibition reprograms CD8<sup>+</sup> T lymphocytes into memory stem cells with potent antitumor effectsVivek Verma, Nazli Jafarzadeh, Shannon Boi, et al.
Cancer Research|October 21, 2016
mTORC2 Signaling Drives the Development and Progression of Pancreatic CancerDavid R Driscoll, Saadia A Karim, Makoto Sano, et al.
Cancer Research|July 18, 2024
Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast CancerAlissandra L Hillis, Timothy D Martin, Haley E Manchester, et al.
Pageof 68